{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:34:16Z","timestamp":1787758456399,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Interleukin-6 (IL-6) is an important mediator in the acute phase of inflammatory diseases such as neuromyelitis optica (NMO) and multiple sclerosis (MS). The level of IL-6 is higher in cerebrospinal fluid and serum of NMO patients compare to MS. Vitamin D has a regulatory effect on IL-6, so it may have a negative correlation with IL-6 in the acute phase of these diseases. This study was performed to evaluate the serum levels of IL-6 and Vitamin D in NMO and MS patients at the onset of disease to find differences that may help in early diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This case\u2013control study was done on patients with the first episode of optic neuritis, transverse myelitis, and area postrema syndrome who were referred to Kashani MS Center in Isfahan, Iran, between January 2018 and January 2020. The serum levels of Vitamin D and IL-6 were assessed using enzyme-linked immunosorbent assay in blood sample taken at the time of first presentation in patients who had a definitive diagnosis of NMO and MS during subsequent workup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      During a 2-year follow-up, definitive diagnosis of NMO was given in 25 cases, and they were compared with 25 cases that were randomly selected from patients with definite MS. Nineteen patients in the NMO group and 21 patients in the MS group were female. The mean age of patients in the NMO and MS groups was 29.64 \u00b1 1.47 and 30.20 \u00b1 1.42, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.46). The mean of serum level of Vitamin D was 24.88 \u00b1 15.2 in NMO patients and 21.56 \u00b1 18.7 in MS patients without significant difference (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.48). The mean of IL-6 was 30.1 \u00b1 22.62 in the NMO group and 23.35 \u00b1 18.8 in the MS group without significant difference (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.28). The serum levels of Vitamin D were insufficient in both groups. No correlation between Vitamin D and IL-6 levels was found in our study (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results showed that serum IL-6 levels were higher at the onset of NMO disease compared with MS. The serum levels of Vitamin D were low in both groups and there was no association between serum levels of Vitamin D and IL-6 in either group. Future studies with large sample size are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_796_21","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T07:30:42Z","timestamp":1664263842000},"page":"67","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica"],"prefix":"10.4103","volume":"27","author":[{"given":"Fereshteh","family":"Ashtari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhanehsadat","family":"Madanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayyed Hamid","family":"Zarkesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Ghalamkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-67-20240830","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-67-20240830","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/jnnp.2007.133785","article-title":"Change in disability in patients with multiple sclerosis: A 20-year prospective population-based analysis","volume":"79","author":"Hirst","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R3-67-20240830","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/01.wnl.0000275228.13012.7b","article-title":"Pathogenesis of myelin\/oligodendrocyte damage in multiple sclerosis","volume":"68","author":"Dhib-Jalbut","year":"2007","journal-title":"Neurology"},{"key":"R4-67-20240830","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.4049\/jimmunol.180.9.6411","article-title":"Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression","volume":"180","author":"Venken","year":"2008","journal-title":"J Immunol"},{"key":"R5-67-20240830","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08916934.2017.1281914","article-title":"B cells in multiple sclerosis","volume":"50","author":"Wekerle","year":"2017","journal-title":"Autoimmunity"},{"key":"R6-67-20240830","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(00)01543-3","article-title":"Interleukin-6 expression in human multiple sclerosis lesions","volume":"294","author":"Sch\u00f6nrock","year":"2000","journal-title":"Neurosci Lett"},{"key":"R7-67-20240830","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"R8-67-20240830","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"R9-67-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"R10-67-20240830","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11910-008-0066-2","article-title":"Neuromyelitis optica: Diagnosis, pathogenesis, and treatment","volume":"8","author":"Cree","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R11-67-20240830","first-page":"5314541","article-title":"Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: Pathophysiological and therapeutic implications","volume":"2016","author":"Dos Passos","year":"2016","journal-title":"Mediators Inflamm"},{"key":"R12-67-20240830","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-67-20240830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneuroim.2003.12.010","article-title":"CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis","volume":"149","author":"Narikawa","year":"2004","journal-title":"J Neuroimmunol"},{"key":"R14-67-20240830","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J Neurol"},{"key":"R15-67-20240830","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"R16-67-20240830","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"R17-67-20240830","first-page":"8187","article-title":"Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management?","volume":"24","author":"Orr\u00f9","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R18-67-20240830","doi-asserted-by":"crossref","first-page":"102156","DOI":"10.1016\/j.msard.2020.102156","article-title":"The potential immunoregulatory roles of vitamin D in neuromyelitis optica spectrum disorder","volume":"43","author":"Wu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R19-67-20240830","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.3346\/jkms.2020.35.e40","article-title":"1,25-dihydroxy vitamin D3 and interleukin-6 blockade synergistically regulate rheumatoid arthritis by suppressing interleukin-17 production and osteoclastogenesis","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"R20-67-20240830","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"R21-67-20240830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R22-67-20240830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jocn.2018.11.024","article-title":"Low levels of vitamin D and the relationship between vitamin D and Th2 axis-related cytokines in neuromyelitis optica spectrum disorders","volume":"61","author":"Gao","year":"2019","journal-title":"J Clin Neurosci"},{"key":"R23-67-20240830","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2018.08.030","article-title":"Low vitamin D-25(OH) level in Indonesian multiple sclerosis and neuromyelitis optic patients","volume":"25","author":"Kusumadewi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R24-67-20240830","doi-asserted-by":"crossref","first-page":"e107274","DOI":"10.1371\/journal.pone.0107274","article-title":"Low levels of vitamin D in neuromyelitis optica spectrum disorder: Association with disease disability","volume":"9","author":"Min","year":"2014","journal-title":"PLoS One"},{"key":"R25-67-20240830","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2016.03.016","article-title":"Vitamin D level status in Thai neuromyelitis optica patients","volume":"295-296","author":"Jitprapaikulsan","year":"2016","journal-title":"J Neuroimmunol"},{"key":"R26-67-20240830","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13167-017-0120-8","article-title":"Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases","volume":"8","author":"Koduah","year":"2017","journal-title":"EPMA J"},{"key":"R27-67-20240830","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol"},{"key":"R28-67-20240830","doi-asserted-by":"crossref","first-page":"1756284820923922","DOI":"10.1177\/1756284820923922","article-title":"The association between circulating levels of vitamin D and inflammatory markers in the first 2 years after colorectal cancer diagnosis","volume":"13","author":"Wesselink","year":"2020","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_796_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:15:02Z","timestamp":1787757302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_796_21"}},"subtitle":["A pilot study"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_796_21","relation":{},"ISSN":["1735-1995"],"issn-type":[{"value":"1735-1995","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}